Capital Management Iv, Llc ... Net Worth

The estimated Net Worth of Capital Management Iv, Llc ... is at least $1.38 Million dollars as of 8 May 2023. Capital Llc owns over 1,780,000 units of Kinnate Biopharma stock worth over $1,379,884 and over the last 2 years Capital sold KNTE stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Capital Llc KNTE stock SEC Form 4 insiders trading

Capital has made over 1 trades of the Kinnate Biopharma stock since 2023, according to the Form 4 filled with the SEC. Most recently Capital bought 1,780,000 units of KNTE stock worth $4,984,000 on 8 May 2023.

The largest trade Capital's ever made was buying 1,780,000 units of Kinnate Biopharma stock on 8 May 2023 worth over $4,984,000. On average, Capital trades about 890,000 units every 0 days since 2023. As of 8 May 2023 Capital still owns at least 520,711 units of Kinnate Biopharma stock.

You can see the complete history of Capital Llc stock trades at the bottom of the page.

Insiders trading at Kinnate Biopharma

Over the last 4 years, insiders at Kinnate Biopharma have traded over $0 worth of Kinnate Biopharma stock and bought 12,223,600 units worth $79,803,534 . The most active insiders traders include Carl L Gordon, Advisors Llc Orbi Med Capit..., and Helen Sabzevari. On average, Kinnate Biopharma executives and independent directors trade stock every 74 days with the average trade being worth of $2,699,377. The most recent stock trade was executed by James B. Tananbaum on 8 May 2023, trading 1,780,000 units of KNTE stock currently worth $4,984,000.

What does Kinnate Biopharma do?

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

Complete history of Capital Llc stock trades at Kinnate Biopharma

Kinnate Biopharma executives and stock owners

Kinnate Biopharma executives and other stock owners filed with the SEC include:

• Nima Farzan M.B.A.,
  Pres, CEO & Director
• Mark A. Meltz,
  COO, Gen. Counsel, Treasurer & Sec.
• Neha Krishnamohan,
  CFO, Principal Accounting Officer and Exec. VP of Corp. Devel.
• Dr. Eric Anthony Murphy Ph.D.,
  Chief Scientific Officer
• Jason Hampson M.D.,
  VP and Head of Regulatory Affairs & Quality
• Priyanka Shah,
  VP of Investor Relations & Communications
• Ken Kobayashi M.D.,
  Sr. VP of Clinical Devel.
• Jason Hampson,
  VP & Head of Regulatory Affairs
• Barbara Warren,
  VP of People & Culture
• Eric Martin Ph.D.,
  Sr. VP of Translational Medicine
• Dr. Robert Kania Ph.D.,
  Sr. VP of Drug Discovery
• Dr. Richard Thomas Williams MBBS, Ph.D.,
  Chief Medical Officer
• Nima Farzan,
  Pres, CEO & Director
• Capital Management Iv, Llc ...,
  
• Eric Anthony Murphy,
  Chief Scientific Officer
• Helen Sabzevari,
  
• Alsup Laurie Smaldone,
  
• James B. Tananbaum,
  
• Dean J Mitchell,
  
• Keith T. Flaherty,
  
• Advisors Llc Orbi Med Capit...,
  
• Advisors Llc Orbi Med Capit...,
  
• Michael E Rome,
  
• Melissa B, Epperly,
  
• Carl L Gordon,
  Director
• Capital Management Iv, Llc ...,
  
• Advisors Llc Orbi Med Capit...,
  
• Jill De Simone,
  
• Neha Krishnamohan,
  CHIEF FINANCIAL OFFICER
• Mark A Meltz,
  COO GENERAL COUNSEL SECRETARY
• Richard Thomas Williams,
  CHIEF MEDICAL OFFICER
• Nima Farzan,
  CHIEF EXECUTIVE OFFICER